Drawing for Serial No. 87416777

USPTO serial 87416777

Serial No. 87416777

Reviewed by CopyMark Law Group

Reg. 5388433Status 710
Filing date
Status date
Registration date
Jan 23, 2018
Examiner
VERHOSEK, WILLIAM T
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with Serial No. 87416777?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David D'Zurilla

DAVID D'ZURILLA SCHWEGMAN LUNDBERG & WOESSNER, P.A.P.O. BOX 2938MINNEAPOLIS, MN 55402UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and biopharmaceutical drugs for the treatment of pain, inflammation, cancer, seizures, and epilepsySECTION 8 - CANCELLEDNov 1, 2017
040Custom manufacture of pharmaceuticals and biopharmaceutical drugs; Custom manufacturing of new biological products for others; Custom manufacture of chemical products for others; Custom manufacture of nutraceuticals for others; Custom manufacture of cosmeceuticals for others; Custom manufacture of medical veterinary products for othersSECTION 8 - CANCELLEDJul 1, 2016
042Research and development of pharmaceuticals and biopharmaceutical drugs; Medical research and development in the field of synthetic biology, molecular biology, genetic engineering, and organic chemistry; Research and development of new biological products for others; Research and development of new chemical products for others; Nutraceutical research and development for others; Cosmeceutical research and development for others; Veterinary medical research and development for others; Research and development in the field of bioinformatics and proteomicsSECTION 8 - CANCELLEDJul 1, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 2, 2024C8..CANCELLED SEC. 8 (6-YR)—
Jan 23, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 23, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 20, 2017SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Dec 19, 2017CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Dec 19, 2017SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Dec 15, 2017AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 1, 2017IUAFUSE AMENDMENT FILED—
Dec 1, 2017EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Oct 10, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 15, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 15, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 26, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 13, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 13, 2017ALIEASSIGNED TO LIE—
Jun 8, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 7, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Jun 7, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 7, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 7, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 6, 2017DOCKASSIGNED TO EXAMINER—
Apr 26, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 25, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 22, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance